[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:rad51d-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"RAD51D Gene",20,15,[8,16,23,30,36,43,49,55,61,67,73,79,85,91,97,103,110,116,122,129],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05687110","Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes",[12],"Phase 1","RECRUITING","2026-08-26T02:17:58.890423Z","2026-05-05T02:43:27.808389Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT03786796","Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations",[20],"Phase 2","2026-08-26T02:18:38.077159Z","2026-05-05T02:35:31.766251Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT05659381","Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer",[27],"Phase 3","2026-08-26T02:17:14.343713Z","2026-05-05T02:43:27.677486Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT06458712","Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies",[12],"2026-08-26T02:15:51.395565Z","2026-07-24T01:27:14.872137Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":41,"content_modified":42},"NCT05417594","Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies",[40],"Phase 1\u002FPhase 2","2026-08-26T02:18:54.586325Z","2026-05-05T02:43:28.529406Z",{"nct_id":44,"title":45,"phases":46,"status":13,"updated_at":47,"content_modified":48},"NCT05287451","Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study",[],"2026-08-26T02:15:44.309045Z","2026-07-05T05:32:16.798306Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":53,"content_modified":54},"NCT04294927","TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention",[],"2026-08-26T02:15:25.633039Z","2026-05-05T02:43:27.631193Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT05941520","Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer",[20],"2026-08-26T02:17:39.048487Z","2026-07-19T19:36:05.126907Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT06195306","Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction",[20],"2026-08-26T02:18:31.164304Z","2026-05-05T02:43:26.724920Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT07645391","Targeted Early Detection Program in Men at High Genetic Risk for Prostate Cancer",[],"2026-08-26T02:16:05.813655Z","2026-06-14T18:39:22.265063Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT07076147","Breast Cancer Screening Adherence for Women at Moderate Risk for Breast Cancer",[],"2026-08-26T02:19:06.150683Z","2026-05-13T02:55:06.650047Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT07038785","Identification of Breast Cancer in Breath Samples Using Trained Detection Dogs",[],"2026-08-26T02:18:38.865010Z","2026-05-13T02:55:06.608906Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT05129605","Prostate Cancer Genetic Risk Evaluation and Screening Study",[],"2026-08-26T02:18:25.327036Z","2026-05-13T02:55:06.292506Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT03805919","Men at High Genetic Risk for Prostate Cancer",[],"2026-08-26T02:15:18.897219Z","2026-05-13T02:55:06.177945Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT04038502","Carboplatin or Olaparib for BRcA Deficient Prostate Cancer",[20],"2026-08-26T02:18:40.612983Z","2026-05-05T02:43:29.505079Z",{"nct_id":104,"title":105,"phases":106,"status":107,"updated_at":108,"content_modified":109},"NCT07565155","Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency",[20],"NOT_YET_RECRUITING","2026-08-26T02:15:15.642947Z","2026-05-13T02:55:06.729176Z",{"nct_id":111,"title":112,"phases":113,"status":107,"updated_at":114,"content_modified":115},"NCT07723651","[18F]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC)",[20],"2026-08-26T02:19:11.399072Z","2026-07-24T01:27:14.924205Z",{"nct_id":117,"title":118,"phases":119,"status":107,"updated_at":120,"content_modified":121},"NCT07690852","Environmental Exposure Assessment in High-Risk and Early-Onset Breast Cancer Care",[],"2026-08-26T02:16:24.970704Z","2026-07-19T19:36:05.153122Z",{"nct_id":123,"title":124,"phases":125,"status":126,"updated_at":127,"content_modified":128},"NCT05498272","Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations",[20],"ACTIVE_NOT_RECRUITING","2026-08-03T02:05:27.322885Z","2026-05-05T02:43:27.674415Z",{"nct_id":130,"title":131,"phases":132,"status":126,"updated_at":133,"content_modified":134},"NCT04550494","Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations",[20],"2026-08-03T03:54:23.387833Z","2026-05-05T02:43:29.385344Z"]